Stock Fundamentals

Company Information

Company Name
Mesoblast Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US5907171046
CIK: 0001345099
CUSIP: 590717104
Currency: USD
Full Time Employees: 81
Phone: 61 3 9639 6036
Fiscal Year End: June
IPO Date: Nov 13, 2015
Description:

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Address:

55 Collins Street, Melbourne, VIC, Australia, 3000

Directors & Officers

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Executive Director 1951
Mr. James Michael O'Brien CPA, M.B.A. Chief Financial Officer 1966
Mr. Paul Hughes BPHARM Global Head of Corporate Communications & Joint Company Secretary NA
Dr. Paul J. Simmons BSc, Ph.D. Scientific Advisor to the Chief Executive Officer 1959
Ms. Geraldine Storton B.Sc., M.B.A., MMS Head of Regulatory Affairs & Quality Management NA
Mr. Daniel Devine B.Sc., J.D., M.B.A Head of Special Projects NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Dr. Fiona See Ph.D. Senior VP & Head of Translational Research NA
Mr. Marcelo Santoro Chief Commercial Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 10, 2026 Gregory George N/A Purchase 2.32M $1.48 $3.44M
Apr 09, 2026 Gregory George N/A Purchase 1.59M $1.44 $2.29M
Apr 09, 2026 Gregory George N/A Purchase 1.98M $8.59 $17.02M
Apr 04, 2026 Gregory George N/A Purchase 4.00M $1.42 $5.68M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 630.86K Mar 31, 2026 0.49% $0.00 -6.73%
Morgan Stanley - Brokerage Accounts 514.43K Mar 31, 2026 0.40% $0.00 -13.82%
The Goldman Sachs Group Inc 397.22K Mar 31, 2026 0.31% $0.00 0.34%
Susquehanna International Group, LLP 386.47K Mar 31, 2026 0.30% $0.00 -10.09%
UBS Group AG 132.57K Mar 31, 2026 0.10% $0.00 82.71%
Bank of America Corp 100.00K Mar 31, 2026 0.08% $0.00 608.44%
Jane Street Group LLC 98.79K Mar 31, 2026 0.08% $0.00 -40.98%
Penbrook Management LLC 87.08K Mar 31, 2026 0.07% $1.01 -0.57%
Citadel Advisors Llc 85.96K Mar 31, 2026 0.07% $0.00 -34.58%
M&G PLC 59.10K Mar 31, 2026 0.05% $0.00 0.00%
Prosperity Wealth Management Inc 50.90K Dec 31, 2025 0.04% $0.31 1.90%
LPL Financial Corp 49.62K Mar 31, 2026 0.04% $0.00 1.78%
Rialto Wealth Management, LLC 46.50K Mar 31, 2026 0.04% $0.16 0.00%
XTX Topco Ltd 40.92K Mar 31, 2026 0.03% $0.01 227.27%
Two Sigma Investments LLC 39.80K Mar 31, 2026 0.03% $0.00 -30.85%
HRT FINANCIAL LLC 34.22K Mar 31, 2026 0.03% $0.00 0.00%
Squarepoint Ops LLC 34.04K Mar 31, 2026 0.03% $0.00 83.23%
Geode Capital Management, LLC 33.75K Mar 31, 2026 0.03% $0.00 9.79%
Wiley Bros.-Aintree Capital, LLC 26.95K Mar 31, 2026 0.02% $0.00 45.56%
Citigroup Inc 26.46K Mar 31, 2026 0.02% $0.00 0.25%

Shares Statistics

Shares Outstanding: 129.28M
Shares Float: 83.38M
% Insiders: 505.10%
% Institutions: 279.70%
Short % Float: 3.24%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Biotechnology ETF 454.58K 0.35% ▲ 1.95% May 29, 2026
2 M&G Recovery GBP A Acc 59.10K 0.05% ▲ 0.00% Feb 28, 2026
3 iShares Nasdaq US Biotech ETF USD Acc 36.59K 0.03% ▲ 0.00% May 29, 2026
4 Fidelity Nasdaq Composite Index 33.75K 0.03% ▲ 0.00% Apr 30, 2026
5 China Universal NASDAQ Bio-Tch ETF(QDII) 7.99K 0.01% ▼ 12.41% Dec 31, 2025
6 Steward Values Enhanced International I 6.51K 0.01% ▲ 0.00% Apr 30, 2026
7 ActivePassive International Equity ETF 6.32K 0.00% ▲ 0.00% May 29, 2026
8 Invesco Nasdaq Biotechnology ETF 2.77K 0.00% ▲ 0.00% May 29, 2026
9 ProShares Ultra Nasdaq Biotechnology 1.93K 0.00% ▲ 0.00% May 29, 2026
10 Xtrackers MSCI Genomic HC Inno ETF 1C 1.72K 0.00% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $1.78B
Trailing P/E: 0.00
Forward P/E: 454.55

Financial Highlights

Market Cap: $1.80B
EBITDA: $-64.34M
PEG Ratio: $0.00
Book Value: $4.46
Earnings/Share: $-0.66
Profit Margin: -144.33%
Operating Margin: -55.16%
ROA (TTM): -6.16%
ROE (TTM): -18.22%
Revenue (TTM): $65.38M
Revenue/Share (TTM): $0.51
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 1,526.80%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-06-30 1.99x 0.21x 0.24x -2.72x -1.69x
2024-06-30 1.18x 0.24x 0.28x -4.07x -2.09x
2023-06-30 1.95x 0.22x 0.25x -3.56x -1.93x
2022-06-30 1.36x 0.20x 0.25x -4.66x -1.30x
2021-06-30 1.57x 0.17x 0.22x -10.18x -1.15x
2020-06-30 1.51x 0.17x 0.25x -5.09x -1.35x
2019-06-30 1.41x 0.17x 0.26x -6.85x -0.96x
2018-06-30 4.21x 0.22x 0.21x -42.28x -1.59x
2017-06-30 1.73x 0.00x 0.21x N/A 0.00x
2016-06-30 3.02x 0.00x 0.23x -6.00x 0.00x
2015-06-30 2.53x 0.00x 0.40x -10.77x 0.00x
2014-06-30 4.77x 0.01x 0.36x -16.72x -0.08x
2013-06-30 6.56x 0.00x 0.29x N/A 0.00x
2012-06-30 4.89x 0.01x 0.34x -168,590.07x -0.07x
2011-06-30 8.62x 0.00x 0.32x 6,287.67x 0.00x
2010-06-30 21.01x 0.00x 0.04x N/A 0.00x
2009-06-30 14.28x 0.00x 0.04x N/A 0.00x
2008-06-30 9.09x 0.00x 0.06x N/A 0.00x
2007-06-30 18.02x 0.00x 0.03x -12,939.97x 0.00x
2006-06-30 1.82x 0.00x 0.27x -57.08x 0.00x
2005-06-30 6.96x 0.00x 0.10x -9.21x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MESO.US!